Home

Person

Bernard Schneider

This person has left EPFL

About
Privacy
Disclaimer

Graph Chatbot

Related publications (107)

Page 2 of 6

alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease

Patrick Aebischer, Bernard Schneider, Nicole Déglon, Christophe Lo Bianco

Parkinson's disease (PD) is characterized by the progressive loss of substantia nigra dopaminergic neurons and the presence of cytoplasmic inclusions named Lewy bodies. Two missense mutations of the alpha-synuclein (alpha-syn; A30P and A53T) have been desc ...

National Academy of Sciences2002

Stable isotope labeling and ultra-high-resolution NanoSIMS imaging reveal alpha-synuclein-induced changes in neuronal metabolism in vivo

Anders Meibom, Graham Knott, Bernard Schneider, Stéphane Laurent Escrig, Louise Helene Soegaard Jensen, Bohumil Maco, Sofia Carmen Suzanne Spataro

In Parkinson's disease, pathogenic factors such as the intraneuronal accumulation of the protein alpha-synuclein affect key metabolic processes. New approaches are required to understand how metabolic dysregulations cause degeneration of vulnerable subtype ...

2023

FOXO3 determines the accumulation of alpha-synuclein and controls the fate of dopaminergic neurons in the substantia nigra

Bernard Schneider, Graham Knott, Juan-Carlos Sarria, Emilda Pino, Lu Zheng

Parkinson's disease (PD) is characterized by the selective degeneration of neuronal populations presumably due to pathogenic interactions between aging and predisposing factors such as increased levels of a-synuclein. Here, we genetically modulate the acti ...

Oxford University Press2014

A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity

Patrick Aebischer, Bernard Schneider, Liliane Glauser, Klodjan Stafa, Julien Dusonchet

Mutations in LRRK2 are one of the primary genetic causes of Parkinson's disease (PD). LRRK2 contains a kinase and a GTPase domain, and familial PD mutations affect both enzymatic activities. However, the signaling mechanisms regulating LRRK2 and the pathog ...

Oxford University Press2014

SMN Depleted Mice Offer a Robust and Rapid Onset Model of Nonalcoholic Fatty Liver Disease

Bernard Schneider

BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) is considered a health epidemic with potential devastating effects on the patients and the healthcare systems. Current preclinical models of NAFLD are invariably imperfect and generally take a lon ...

2021

A self-immunomodulating myoblast cell line for erythropoietin delivery

Patrick Aebischer, Bernard Schneider

The transplantation of genetically engineered cells faces limitations associated with host immunity. Allogeneic cells are typically rejected in response to inherent histo-incompatibility. Even autologous cells can induce an immune response toward antigenic ...

2001

alpha-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease occurs independent of ATP13A2 (PARK9)

Bernard Schneider, Liliane Glauser, Elpida Tsika, Alessandra Musso, Guillaume Daniel

Mutations in the ATP13A2 (PARK9) gene cause early-onset, autosomal recessive Parkinson's disease (PD) and Kufor-Rakeb syndrome. ATP13A2 mRNA is spliced into three distinct isoforms encoding a P5-type ATPase involved in regulating heavy metal transport acro ...

Academic Press Inc Elsevier Science2015

Lentiviral vector-mediated genetic modification of human neural progenitor cells for ex vivo gene therapy

Patrick Aebischer, Bernard Schneider, Romain Zufferey

Human neural progenitor cells (hNPC) hold great potential as an ex vivo system for delivery of therapeutic proteins to the central nervous system. When cultured as aggregates, termed neurospheres, hNPC are capable of significant in vitro expansion. In the ...

2007

Delivery of erythropoietin by encapsulated myoblasts in a genetic model of severe anemia

Patrick Aebischer, Bernard Schneider, Nicole Déglon

BACKGROUND: Existing animal models of anemia inadequately reflect the hematocrit usually present in chronic renal failure (CRF) patients and do not permit long-term treatment studies. The transgenic mouse strain 134.3LC (Epo-TAg(H)) displays a severe chron ...

2002

Endoplasmic Reticulum Stress Is Important for the Manifestations of alpha-Synucleinopathy In Vivo

Bernard Schneider, Ying Liu, Philippe Guillaume Coune

Accumulation of misfolded alpha-synuclein (alpha S) is mechanistically linked to neurodegeneration in Parkinson's disease (PD) and other alpha-synucleinopathies. However, how alpha S causes neurodegeneration is unresolved. Because cellular accumulation of ...

Society for Neuroscience2012

Channel-Mediated Lactate Release by K+-Stimulated Astrocytes

Pierre Magistretti, Patrick Aebischer, Bernard Schneider, Sylvain Eric Lengacher

Excitatory synaptic transmission is accompanied by a local surge in interstitial lactate that occurs despite adequate oxygen availability, a puzzling phenomenon termed aerobic glycolysis. In addition to its role as an energy substrate, recent studies have ...

Society for Neuroscience2015

Nano-imaging trace elements at organelle levels in substantia nigra overexpressing alpha-synuclein to model Parkinson's disease

Bernard Schneider, Graham Knott, Philippe André Guy Colin

Sub-cellular trace element quantifications of nano-heterogeneities in brain tissues offer unprecedented ways to explore at elemental level the interplay between cellular compartments in neurodegenerative pathologies. We designed a quasi-correlative method ...

NATURE PUBLISHING GROUP2020

Glutaredoxin 1 Downregulation in the Substantia Nigra Leads to Dopaminergic Degeneration in Mice

Bernard Schneider

Background Parkinson's disease (PD) is characterized by a severe loss of the dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc). Perturbation of protein thiol redox homeostasis has been shown to play a role in the dysregulation of cell ...

2020

Scalable Production of AAV Vectors in Orbitally Shaken HEK293 Cells

Vivianne Padrun, Florian Maria Wurm, Bernard Schneider, Nicole Déglon

Adeno-associated virus (AAV) vectors are currently among the most commonly applied for in vivo gene therapy approaches. The evaluation of vectors during clinical development requires the production of considerable amounts of highly pure and potent vectors. ...

2019

Genetic engineering of cell lines using lentiviral vectors to achieve antibody secretion following encapsulated implantation

Patrick Aebischer, Bernard Schneider, Marc Moniatte, Aurélien Lathuilière

The controlled delivery of antibodies by immunoisolated bioimplants containing genetically engineered cells is an attractive and safe approach for chronic treatments. To reach therapeutic antibody levels there is a need to generate renewable cell lines, wh ...

Elsevier2014

Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates

Patrick Aebischer, Bernard Schneider

Glial cell line-derived neurotrophic factor (GDNF) has been shown to increase the survival and functioning of dopamine neurons in a variety of animal models and some recent human trials. However, delivery of any protein to the brain remains a challenge due ...

2006

Perineuronal net digestion with chondroitinase restores memory in mice with tau pathology

Patrick Aebischer, Bernard Schneider

Alzheimer's disease is the most prevalent tauopathy and cause of dementia. We investigate the hypothesis that reactivation of plasticity can restore function in the presence of neuronal damage resulting from tauopathy. We investigated two models with tau h ...

2015

Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson's disease

Patrick Aebischer, Bernard Schneider, Jean-Charles Bensadoun, Julien Dusonchet

Loss of function of parkin, an ubiquitin ligase, is responsible for autosomal recessive juvenile parkinsonism (AR-JP). Parkin-associated endothelin receptor-like receptor (Pael-R) was identified as an authentic substrate of parkin and is thought to accumul ...

2009

Tmc gene therapy restores auditory function in deaf mice

Patrick Aebischer, Bernard Schneider, Cylia Cloé Rochat

Genetic hearing loss accounts for up to 50% of prelingual deafness worldwide, yet there are no biologic treatments currently available. To investigate gene therapy as a potential biologic strategy for restoration of auditory function in patients with genet ...

American Association for the Advancement of Science2015

An in vivo ultrahigh field 14.1 T (1) H-MRS study on 6-OHDA and α-synuclein-based rat models of Parkinson's disease: GABA as an early disease marker

Rolf Gruetter, Patrick Aebischer, Bernard Schneider, Mélanie Craveiro, Philippe Guillaume Coune, Meret Gaugler

The detection of Parkinson's disease (PD) in its preclinical stages prior to outright neurodegeneration is essential to the development of neuroprotective therapies and could reduce the number of misdiagnosed patients. However, early diagnosis is currently ...

Wiley-Blackwell2013